Abstract: Objective To discuss the cause of disease and the correlation factor for neonatal respiratory failure,and evaluate the clinical effect of (pulmonary surfactant,PS) and subsidiary ventilation for the treatment of neonatal respiratory failure. Methods By retrospective analysis the clinical data of 121 neonatal with respiratory failure were received the systemic treatment of subsidiary ventilation at department of neonatology in the First People's Hospital in Zunyi from July 2010 to July 2011.49 infants who received PS treatment were set as in test group,another 72 neonates who only received subsidiary ventilation were set as control group.The ventilation duration,the total oxygen-inhale time,cure rate,mortality and the clinical outcomes were compared between two groups. Results Cure rate in the test group ( 89.8%) was obviously higher than that in the control group(69.4%);while the mortality rate was lower than that of the control group(χ²=7.16,P＜0.05);The ventilation duration and total oxygen-inhale time in test group were lower compared with control group(U=20.979 and 12.997,P＜0.01);There was no significant difference in the complications between two groups(P＞0.05). Conclusion The combined treatment of PS and subsidiary ventilation can obviously improve the cure rate but not increase the incidence of complications.

Key words: pulmonary surfactant, subsidiary ventilation, respiratory failure, infant, newborn

摘要： 目的 研究新生儿呼吸衰竭的病因及发病因素,探讨肺表面活性物质(pulmonary surfactant,PS)联合辅助通气在新生儿呼吸衰竭中的治疗效果。 【方法 】 回顾性分析2010年7月-2011年7月遵义市第一人民医院新生儿科收治的121例新生儿呼吸衰竭患儿的病例资料,所有病例均给予呼吸支持为主的综合治疗,联合应用肺表面活性物质的49例为试验组,同期单用辅助通气治疗的72例为对照组,比较两组患儿的辅助通气持续时间、总氧疗时间、治愈率、死亡率及并发症发生率。 结果 试验组的治愈率(89.8%)高于对照组(69.4%),死亡率低于对照组(χ²=7.16,P＜0.05);试验组的辅助通气持续时间及总氧疗时间明显低于对照组(U=20.979和12.997,P均＜0.01);两组的并发症发生率差异无统计学意义(P均＞0.05)。 结论 肺表面活性物质联合辅助通气为主的综合治疗可明显提高呼吸衰竭患儿的治愈率,同时不增加并发症的发生率。

关键词: 呼吸衰竭, 婴儿, 新生, 肺表面活性物质, 辅助通气